alnylam pharmaceuticals inc
(ALNY:Consolidated Issue Listed on NASDAQ Global Select )
Judy Lieberman M.D., Ph.D.
Member of Scientific Advisory Board, Alnylam Pharmaceuticals, Inc.
|Age||Total Calculated Compensation||This person is connected to 24 board members in 2 different organizations across 2 different industries.|
See Board Relationships
Dr. Judy Lieberman, M.D., Ph.D. is Professor of pediatrics at the Harvard Medical School, Director of the Division of AIDS at Harvard Medical School, and a senior investigator in the Immune Disease Institute. Dr. Lieberman is board certified in internal medicine and hematology, a widely known expert in translational medicine, and a pioneer in the therapeutic use of RNAi, particularly through the development of innovative delivery tools. Dr. Lieberman and her colleagues ...
300 Third StreetPhone: 617-551-8200
Cambridge, Massachusetts 02142
Board Members Memberships*There is no Board Members Memberships data available.
Massachusetts Institute of Technology
Annual Compensation*There is no Annual Compensation data available.
Stock Options*There is no Stock Options data available.
Total Compensation*There is no Total Compensation data available.
|Ali Mortazavi||Chief Executive and Director|
Silence Therapeutics plc
|J. Michael French||Chairman, Chief Executive Officer and President|
Marina Biotech, Inc.
|Peter French B.Sc, M.Sc, Ph.D., MBA||Chief Executive Officer, Managing Director and Director|
Benitec Biopharma Limited
|Mark Joseph Murray Ph.D.||Chief Executive Officer, President and Director|
Tekmira Pharmaceuticals Corporation
|$580.0K||Compensation as of Fiscal Year 2013.|